VERO Quote, Financials, Valuation and Earnings

Edwards Lifesciences Corp. has a net margin of -163.68% compared to Venus Concept, Inc.'s net margin of 4.09%. Venus Concept, Inc.'s return on equity of -1236.95% beat Edwards Lifesciences Corp.'s return on equity of 13.19%.

Venus Concept, Inc. has a consensus price target of --, signalling upside risk potential of 22318.76%. On the other hand Edwards Lifesciences Corp. has an analysts' consensus of $96.61 which suggests that it could grow by 21.78%. Given that Venus Concept, Inc. has higher upside potential than Edwards Lifesciences Corp., analysts believe Venus Concept, Inc. is more attractive than Edwards Lifesciences Corp..

Venus Concept, Inc. has a beta of -0.011, which suggesting that the stock is 101.098% less volatile than S&P 500. In comparison Edwards Lifesciences Corp. has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.133%.

Venus Concept, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edwards Lifesciences Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Venus Concept, Inc. pays -- of its earnings as a dividend. Edwards Lifesciences Corp. pays out -- of its earnings as a dividend.

Venus Concept, Inc. quarterly revenues are $13.8M, which are smaller than Edwards Lifesciences Corp. quarterly revenues of $1.6B. Venus Concept, Inc.'s net income of -$22.5M is lower than Edwards Lifesciences Corp.'s net income of $64.2M. Notably, Venus Concept, Inc.'s price-to-earnings ratio is -- while Edwards Lifesciences Corp.'s PE ratio is 42.82x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Venus Concept, Inc. is 0.01x versus 7.66x for Edwards Lifesciences Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Nutriband, Inc. has a net margin of -163.68% compared to Venus Concept, Inc.'s net margin of -1118.87%. Venus Concept, Inc.'s return on equity of -1236.95% beat Nutriband, Inc.'s return on equity of -164.64%.

Venus Concept, Inc. has a consensus price target of --, signalling upside risk potential of 22318.76%. On the other hand Nutriband, Inc. has an analysts' consensus of $15.00 which suggests that it could grow by 248.03%. Given that Venus Concept, Inc. has higher upside potential than Nutriband, Inc., analysts believe Venus Concept, Inc. is more attractive than Nutriband, Inc..

Venus Concept, Inc. has a beta of -0.011, which suggesting that the stock is 101.098% less volatile than S&P 500. In comparison Nutriband, Inc. has a beta of 1.886, suggesting its more volatile than the S&P 500 by 88.601%.

Venus Concept, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nutriband, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Venus Concept, Inc. pays -- of its earnings as a dividend. Nutriband, Inc. pays out -- of its earnings as a dividend.

Venus Concept, Inc. quarterly revenues are $13.8M, which are larger than Nutriband, Inc. quarterly revenues of $346.1K. Venus Concept, Inc.'s net income of -$22.5M is lower than Nutriband, Inc.'s net income of -$3.9M. Notably, Venus Concept, Inc.'s price-to-earnings ratio is -- while Nutriband, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Venus Concept, Inc. is 0.01x versus 21.51x for Nutriband, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

STERIS Plc (Ireland) has a net margin of -163.68% compared to Venus Concept, Inc.'s net margin of 12.99%. Venus Concept, Inc.'s return on equity of -1236.95% beat STERIS Plc (Ireland)'s return on equity of 10.4%.

Venus Concept, Inc. has a consensus price target of --, signalling upside risk potential of 22318.76%. On the other hand STERIS Plc (Ireland) has an analysts' consensus of $281.25 which suggests that it could grow by 15.52%. Given that Venus Concept, Inc. has higher upside potential than STERIS Plc (Ireland), analysts believe Venus Concept, Inc. is more attractive than STERIS Plc (Ireland).

Venus Concept, Inc. has a beta of -0.011, which suggesting that the stock is 101.098% less volatile than S&P 500. In comparison STERIS Plc (Ireland) has a beta of 1.030, suggesting its more volatile than the S&P 500 by 3.006%.

Venus Concept, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. STERIS Plc (Ireland) offers a yield of 0.99% to investors and pays a quarterly dividend of $0.63 per share. Venus Concept, Inc. pays -- of its earnings as a dividend. STERIS Plc (Ireland) pays out 35.14% of its earnings as a dividend. STERIS Plc (Ireland)'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Venus Concept, Inc. quarterly revenues are $13.8M, which are smaller than STERIS Plc (Ireland) quarterly revenues of $1.5B. Venus Concept, Inc.'s net income of -$22.5M is lower than STERIS Plc (Ireland)'s net income of $194.4M. Notably, Venus Concept, Inc.'s price-to-earnings ratio is -- while STERIS Plc (Ireland)'s PE ratio is 33.68x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Venus Concept, Inc. is 0.01x versus 4.12x for STERIS Plc (Ireland). Usually stocks with elevated PS ratios are considered overvalued.

Zimmer Biomet Holdings, Inc. has a net margin of -163.68% compared to Venus Concept, Inc.'s net margin of 6.15%. Venus Concept, Inc.'s return on equity of -1236.95% beat Zimmer Biomet Holdings, Inc.'s return on equity of 5.61%.

Venus Concept, Inc. has a consensus price target of --, signalling upside risk potential of 22318.76%. On the other hand Zimmer Biomet Holdings, Inc. has an analysts' consensus of $102.83 which suggests that it could grow by 7.55%. Given that Venus Concept, Inc. has higher upside potential than Zimmer Biomet Holdings, Inc., analysts believe Venus Concept, Inc. is more attractive than Zimmer Biomet Holdings, Inc..

Venus Concept, Inc. has a beta of -0.011, which suggesting that the stock is 101.098% less volatile than S&P 500. In comparison Zimmer Biomet Holdings, Inc. has a beta of 0.619, suggesting its less volatile than the S&P 500 by 38.12%.

Venus Concept, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zimmer Biomet Holdings, Inc. offers a yield of 1% to investors and pays a quarterly dividend of $0.24 per share. Venus Concept, Inc. pays -- of its earnings as a dividend. Zimmer Biomet Holdings, Inc. pays out 27.04% of its earnings as a dividend. Zimmer Biomet Holdings, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Venus Concept, Inc. quarterly revenues are $13.8M, which are smaller than Zimmer Biomet Holdings, Inc. quarterly revenues of $2.2B. Venus Concept, Inc.'s net income of -$22.5M is lower than Zimmer Biomet Holdings, Inc.'s net income of $137.9M. Notably, Venus Concept, Inc.'s price-to-earnings ratio is -- while Zimmer Biomet Holdings, Inc.'s PE ratio is 26.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Venus Concept, Inc. is 0.01x versus 2.31x for Zimmer Biomet Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.